Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
QuintilesIMS
Farmers Insurance
McKesson
UBS
Chubb
Mallinckrodt
Accenture
Healthtrust

Generated: June 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,195,085

« Back to Dashboard

Summary for Patent: 4,195,085
Title: Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
Abstract:Antiglaucoma compositions containing t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate and method of treating elevated intraocular pressure.
Inventor(s): Stone; Clement A. (Blue Bell, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:05/937,696
Patent Claims: 1. A method for treating glaucoma and for lowering intraocular pressure which comprises topically applying to the glaucomatous eye an intraocular pressure lowering effective amount of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate.

2. A method according to claim 1 wherein the t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol is administered in a water soluble polymeric insert.

3. A method according to claim 2 wherein the polymer is hydroxypropylcellulose.

4. A method according to claim 1 wherein the t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol is administered as a 0.01 to 5% solution of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol in an ophthalmologically acceptable carrier.

5. An ophthalmic composition for the topical treatment of glaucoma comprising in solution an intraocular pressure lowering effective amount of t-butylamino-3-(4-morpholino-1,2,5-thiadiazole-3-yloxy)-2-propanol hydrogen maleate and a liquid ophthlamic carrier.

6. A composition according to claim 5 wherein the solution is from 0.01 to 5% t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate.

7. A composition according to claim 5 wherein the solution is from 0.5 to 2% t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Mallinckrodt
Chinese Patent Office
Cantor Fitzgerald
Johnson and Johnson
Merck
Fuji
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.